

CITATION REPORT

List of articles citing

JAK inhibitors: Ten years after

DOI: 10.1002/eji.202048922

European Journal of Immunology, 2021, 51, 1615-1627.

Source: <https://exaly.com/paper-pdf/80595184/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Ruxolitinib Alleviates Uveitis Caused by Endotoxin. <i>Microorganisms</i> , 2021 , 9,	4.9	0
32	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	13
31	JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. <i>Pediatric Rheumatology</i> , 2021 , 19, 146	3.5	2
30	Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2021 , 1-11	5.1	3
29	Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).. <i>Expert Opinion on Therapeutic Patents</i> , 2022 ,	6.8	1
28	Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine.		
27	New drugs under development for COPD.. <i>Minerva Medica</i> , 2022 ,	2.2	0
26	Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
25	Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.. <i>Expert Review of Clinical Immunology</i> , 2022 ,	5.1	0
24	New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	0
23	A multitask GNN-based interpretable model for discovery of selective JAK inhibitors.. <i>Journal of Cheminformatics</i> , 2022 , 14, 16	8.6	1
22	Coumarins derivatives and inflammation: Review of their effects on the inflammatory signaling pathways.. <i>European Journal of Pharmacology</i> , 2022 , 174867	5.3	2
21	Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022 , 60, 131-148	0.9	2
20	IL-13 in dermal type-2 dendritic cell specialization: from function to therapeutic targeting. <i>European Journal of Immunology</i> ,	6.1	0
19	Janus kinase inhibitors in immunoinflammatory rheumatic diseases. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 605-609	0.9	
18	Janus kinase inhibitors for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	1
17	Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. 2022 ,		0

16	Aiming for the pocket.	0
15	JAK-STAT signaling pathway in non-infectious uveitis. 2022 , 204, 115236	0
14	Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.	4
13	IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation. 13,	0
12	JAK: Not Just Another Kinase.	0
11	Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.	0
10	Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis. 9,	0
9	The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. 2022 , 11, 6894	1
8	Double-Stranded RNA Induces Mortality in an MDA5-Mediated Type I Interferonopathy Model. 2022 , 209, 2093-2103	0
7	The inhibition of glycolysis in T cells by a Jak inhibitor ameliorates the pathogenesis of allergic contact dermatitis in mice. 2023 ,	0
6	JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis. 14,	0
5	Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. 2023 , 12, 1734	0
4	A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors. 2023 , 13, 384	0
3	Efficacy of PF-06651600 in alleviating the pro-inflammatory capacity of CD4 + T cells in rheumatoid arthritis patients. 2023 , 26, 740-750	0
2	JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review. 2023 , 16, 279-295	0
1	Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. 2023 , 66, 4378-4416	0